Biotech Stocks on Investors' Radar -- Alexion Pharma, BioMarin Pharma, Merrimack Pharma, and Pacific Biosciences of California

Aug 31, 2016, 07:50 ET from Chelmsford Park SA

NEW YORK, August 31, 2016 /PRNewswire/ --'s focus shifted to Biotechnology industry which uses biological systems or living organisms for the development of biopharmaceutical drugs. Two main catalysts driving stocks in this arena are clinical and regulatory developments. Let us now review today's featured companies: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), and Pacific Biosciences of California Inc. (NASDAQ: PACB). Learn more about these stocks by downloading their comprehensive and free reports at:

Alexion Pharma  

At the close on Tuesday, shares in New Haven, Connecticut headquartered Alexion Pharmaceuticals Inc. rose 0.18%, ending the day at $128.22. The stock recorded a trading volume of 823,792 shares. The Company's shares are trading above their 50-day moving average by 0.57%. Moreover, shares of Alexion Pharmaceuticals, which develops and commercializes life-transforming therapeutic products, have a Relative Strength Index (RSI) of 44.84.

On August 29th, 2016, Alexion Pharmaceuticals announced that the European Commission has granted orphan drug designation to ALXN1007, a novel anti-inflammatory monoclonal antibody targeting complement protein C5a, for the treatment of graft-versus-host disease (GVHD). Alexion is currently investigating ALXN1007 in patients with acute GVHD of the lower gastrointestinal tract (GI-GVHD), a severe and life-threatening rare autoimmune disease that can occur as a complication of stem cell or bone marrow transplantation. ALXN complete research report is just a click away and free at:

BioMarin Pharma  

Shares in San Rafael, California headquartered BioMarin Pharmaceutical Inc. ended the day 0.83% lower at $94.95 with a total trading volume of 712,516 shares. In the previous three months, the stock has gained 8.64%. The Company's shares are trading above their 50-day and 200-day moving averages by 4.53% and 7.52%, respectively. Furthermore, shares of BioMarin Pharmaceutical, which develops and commercializes pharmaceuticals for serious diseases and medical conditions in the US, Europe, Latin America, and internationally, have an RSI of 52.87.

On August 05th, 2016, research firm Stifel reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $107 a share to $113 a share.

As per notes filed on August 11th, 2016 with the SEC, BioMarin Pharmaceutical entered into an underwriting agreement on August 8th, 2016 with Goldman Sachs & Co. and Merrill Lynch, Pierce, Fenner & Smith Inc., as underwriters, pursuant to which the Underwriters agreed to purchase 7,500,000 shares of the company's common stock, par value $0.001 per share, at a price per share of $95.16. Under the terms of the Underwriting Agreement, the company also granted the Underwriters an option exercisable for 30 days to purchase up to an additional 750,000 shares of Common Stock at a price per share of $95.16. The net proceeds to the company from this offering are expected to be approximately $712.9 million. The company intends to use the net proceeds from this offering for general corporate purposes, including clinical trials of its product candidates and the expansion of its manufacturing capacity. The complimentary report on BMRN can be downloaded at:

Merrimack Pharma  

On Tuesday, shares in Cambridge, Massachusetts headquartered Merrimack Pharmaceuticals Inc. finished 1.47% lower at $4.68 with a total volume of 1.47 million shares traded. The stock is trading below its 50-day moving average by 14.01%. Shares of the Company, which engages in discovering, developing and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the US, have an RSI of 35.19.

On August 4th, 2016, Merrimack reported that net loss attributable to the company for Q2 2016 was $50.8 million, or $0.40 per share, compared to a net loss attributable to Merrimack of $38.5 million, or $0.33 per share, for Q1 2016. The company's product revenues from the commercial sale of ONIVYDE were $12.9 million for Q2 2016, compared to $10.0 million for Q1 2016. Sign up for your complimentary research report on MACK at:

Pacific Biosciences of California  

Menlo Park, California headquartered Pacific Biosciences of California Inc.'s stock recorded a trading volume of 1.36 million shares at the end of yesterday's session and closed the day at $8.43, gaining 0.36%. The stock is trading above its 50-day moving average by 3.31%. Shares of the Company, which designs, develops, and manufactures sequencing systems to resolve genetically complex problems, have an RSI at 52.09.

On August 4th, 2016, Pacific Biosciences reported that revenue for Q2 2016 totaled $20.7 million compared to $24.9 million for Q2 2015. The company's product and service revenue for Q2 2016 increased by 51% to $17.1 million compared to $11.3 million for Q2 2015.  Pacific Biosciences' net loss for Q2 2016 was $18.5 million compared to $11.9 million for Q2 2015. Get free access to your research report on PACB at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:  +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA